感染性休克成人患者早期给予氢化可的松、维生素C和硫胺素:一项随机对照临床试验
该单中心、双盲RCT纳入2019年2月至2021年6月苏北人民医院收治的感染性休克成人患者,随机1:1接受干预(氢化可的松200 mg/d、维生素C 2 g每6小时、硫胺素200 mg每12小时)或安慰剂(0.9%氯化钠)治疗5天或至ICU出院。主要终点90天死亡率在符合方案人群中干预组39.9%(81/203) vs 安慰剂组39.0%(80/205),无显著差异(P=0.86);28天死亡率36.5% vs 36.1%(P=0.94)、ICU死亡率31.5% vs 28.8%(P=0.55)、住院死亡率34.5% vs 33.2%(P=0.78)均无显著差异。休克逆转、无血管活性药天数、ICU住院时间等其他次要终点亦无显著差异;意向性分析纳入全部426例患者,结果一致(所有P>0.05)。作者结论认为早期联合治疗未带来生存获益。
要点
- 符合方案人群90天死亡率:干预组39.9%(81/203) vs 安慰剂组39.0%(80/205),P=0.86,无显著差异。
- 28天死亡率干预组36.5% vs 安慰剂组36.1%(P=0.94),ICU死亡率31.5% vs 28.8%(P=0.55),住院死亡率34.5% vs 33.2%(P=0.78),均无显著差异。
- 休克逆转、无血管活性药天数、ICU住院时间等次要终点两组均无显著差异。
- 意向性分析纳入全部426例患者,结果与符合方案分析一致(所有P>0.05)。
- 干预方案为氢化可的松200 mg每日、维生素C 2 g每6小时、硫胺素200 mg每12小时,持续5天或至ICU出院。
适用人群与场景
- 苏北人民医院收治的成人感染性休克患者,休克诊断后12小时内入组,研究期间为2019年2月至2021年6月。
处置流程与药物剂量
- 干预组:氢化可的松200 mg每日、维生素C 2 g每6小时、硫胺素200 mg每12小时,持续5天或至ICU出院。
- 对照组:安慰剂(0.9%氯化钠),给药方案与干预组对应。
研究设计与关键结果
- 单中心、双盲RCT,随机426例,符合方案分析纳入408例(干预组203例、安慰剂组205例)。
- 主要终点90天死亡率:干预组39.9%(81/203) vs 安慰剂组39.0%(80/205),P=0.86,无显著差异。
- 28天死亡率:干预组36.5% vs 安慰剂组36.1%,P=0.94;ICU死亡率:31.5% vs 28.8%,P=0.55;住院死亡率:34.5% vs 33.2%,P=0.78,均无显著差异。
- 休克逆转、无血管活性药天数、ICU住院时间等其他次要终点两组均无显著差异。
- 意向性分析纳入全部426例患者,结果与符合方案分析一致(所有P>0.05)。
证据类型、等级与局限
- 证据类型:单中心、双盲随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,感染性休克成人早期使用氢化可的松、维生素C和硫胺素联合治疗与安慰剂相比未带来生存获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The combination therapy of hydrocortisone, vitamin C, and thiamine has been proposed as a potential treatment in patients with sepsis and septic shock. However, subsequent trials have reported conflicting results in relation to survival outcomes. Hence, we performed this randomized controlled trial (RCT) to evaluate the efficacy and safety of early combination therapy among adult patients with septic shock.
METHODS: This single-center, double-blind RCT enrolled adult patients with diagnosis of septic shock within 12 h from Northern Jiangsu People's Hospital between February 2019 and June 2021. Recruited patients were randomized 1:1 to receive intervention (hydrocortisone 200 mg daily, vitamin C 2 g every 6 h, and thiamine 200 mg every 12 h) or placebo (0.9% saline) for 5 days or until ICU discharge. The primary endpoint was 90-day mortality. The secondary endpoints included mortality at day 28, ICU discharge, and hospital discharge; shock reversal; 72-h Delta SOFA score; ICU-free days, vasopressor-free days, and ventilator support -free days up to day 28; ICU length of stay (LOS) and hospital LOS.
RESULTS: Among 426 patients randomized, a total of 408 patients with septic shock were included in the per-protocol (PP) analysis, of which 203 were assigned to the intervention group and 205 to the placebo group. In the PP population, the primary outcome of 90-day mortality was 39.9% (81/203) and 39.0% (80/205) in the intervention and the placebo groups, respectively, and was not significantly different (P = 0.86). There was no significant difference between two groups in 28-day mortality (36.5% vs. 36.1%, P = 0.94) or the ICU mortality (31.5% vs. 28.8%, P = 0.55) and hospital mortality (34.5% vs. 33.2%, P = 0.78). No other secondary outcomes showed significant differences between two groups, including shock reversal, vasopressor-free days, and ICU LOS. Intention-to-treat analysis included all the 426 patients and confirmed these results (all P > 0.05).
CONCLUSION: Among adult patients with septic shock, early use of hydrocortisone, vitamin C, and thiamine combination therapy compared with placebo did not confer survival benefits. Trial registration ClinicalTrials.gov: NCT03872011 , registration date: March 12, 2019.
参考来源
- Lyu QQ, Zheng RQ, Chen QH, et al. Early administration of hydrocortisone, vitamin C, and thiamine in adult patients with septic shock: a randomized controlled clinical trial. Crit Care. 2022. PMID: 36171582. doi:10.1186/s13054-022-04175-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。